title: Incorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL: is there a right or wrong way?
abstract: Although combination chemotherapy regimens have been clearly successful in treating a proportion of patients with acute leukemia, we are probably close to a ceiling of maximal benefit from such combinations. Identification of targets in the cellular signaling pathways and development of specific drugs against them have added to our armamentarium; our current challenge is how to best incorporate these agents into the currently available regimens.
authors.affiliation: MD Anderson Cancer Center, University of Texas, Houston, TX, USA, fravandi@mdanderson.org.
authors.forename: Farhad
authors.initials: F
authors.lastname: Ravandi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases